LMAT vs TFX
LMAT: LeMaitre Vascular is a medical technology company specializing in the development and manufacturing of innovative devices for peripheral vascular surgery. TFX: Teleflex provides essential, specialty medical technologies used in critical care and surgical procedures to improve patient outcomes.
Side-by-side fundamentals
| Metric | LMAT | TFX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $79.64 | $124.19 | |
| Market cap | $1.8B | $5.3B | |
| P/E as of 2026-10-08 | 28.79 | n/a | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 0.73 | n/a | |
| Net margin FY2025, SEC XBRL | +23.1% | -45.4% | LMAT higher |
| Gross margin FY2025, SEC XBRL | +71.5% | +56.2% | LMAT higher |
| Operating margin FY2025, SEC XBRL | +27.2% | +5.9% | LMAT higher |
| ROE FY2025, SEC XBRL | +14.7% | -29.0% | LMAT higher |
| ROA FY2025, SEC XBRL | +9.4% | -13.0% | LMAT higher |
| Debt / equity as of 2026-09-03 | 0.40 | 0.97 | LMAT lower |
| Revenue growth (YoY) as of 2026-09-03 | +11.8% | -14.5% | LMAT higher |
| Revenue CAGR (3y) SEC XBRL | +15.6% | -10.6% | LMAT higher |
| Dividend yield as of 2026-09-03 | +1.3% | +1.1% | LMAT higher |
| Dividend streak (yrs) SEC XBRL | 15 | 18 | TFX higher |
| Beta as of 2026-09-03 | 0.63 | 0.74 | |
| 1-year return as of 2026-10-08 close | -9.5% | -3.3% | TFX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.